Prognosis of non-Hodgkin's lymphoma

With the continuous improvement of treatment methods, the prognosis of non-Hodgkin's lymphoma has improved significantly, and some subtypes have hope of being cured. The International Prognostic Index (IPI) of non-Hodgkin's lymphoma includes age over 60 years old, stage III or IV, more than one extranodal lesion, need to be bedridden or need care from others, and elevated serum LDH. Based on this, patients are divided into four categories: low risk, low-intermediate risk, high-intermediate risk, and high risk to determine the patient's prognosis.

The low-risk group met 0 to 1 adverse international prognostic indicators, and the complete remission rate after treatment could reach 87%, the 2-year survival rate was 84%, and the 5-year survival rate was 73%; the low-intermediate-risk group met 2 adverse international prognostic indicators, and the complete remission rate after treatment could reach 67%, the 2-year survival rate was 66%, and the 5-year survival rate was 5%; the high-intermediate-risk group met 3 adverse international prognostic indicators, and the complete remission rate after treatment could reach 55%, the 2-year survival rate was 54%, and the 5-year survival rate was 43%; the high-risk group met 4 to 5 adverse international prognostic indicators, and the complete remission rate after treatment could reach 44%, the 2-year survival rate was 34%, and the 5-year survival rate was 26%.

Tips-Efficacy standards for cancer treatment: Complete remission (CR): The visible tumor disappears completely and lasts for more than one month; Partial remission (PR): The tumor volume decreases by more than 50% and lasts for more than one month; Stable disease (NC): The tumor decreases by less than 50% or increases by less than 25% and lasts for more than one month; Progressive disease (PD): The tumor increases by more than 25% or new lesions appear.